University of Cambridge > > SciSoc – Cambridge University Scientific Society > Rejuvenation biotechnology: why age may soon cease to mean aging

Rejuvenation biotechnology: why age may soon cease to mean aging

Add to your list(s) Download to your calendar using vCal

If you have a question about this talk, please contact Maya Ben Yami.

TIME & LOCATION CHANGE - With de Grey being in high demand, his talk will now be SATURDAY 3rd NOVEMBER in the Winstanley lecture theatre, Trinity College.

All other details as before: doors will open 5:45pm for a 6pm start, followed by a Q&A and refreshments.

‘I’d say there is a 50/50 chance we will have brought ageing under decisive control within 20 years. In 100 years, there’s an 80% or 90% chance that we will have achieved that goal’ – Dr Aubrey de Grey in The Guardian, September 2018. Dr De Grey is the Chief Science Officer of the Strategies for Engineered Negligible Senescence (SENS) Research Foundation, a Silicon Valley based non-profit whose goal is to ‘transform the way the world researches and treats age-related diseases’. He is editor-in-chief of the journal Rejuvenation Research, a co-author of the book Ending Aging, and a Vice-President at AgeX, a biotech company applying cellular medicine to age-related diseases. De Grey contends that the fundamental knowledge to develop anti-aging medicines already exists.

The talk is open to the public!

Where: Pfizer lecture theatre, Chemistry department

Members: Free | Non-members: £3

This talk is part of the SciSoc – Cambridge University Scientific Society series.

Tell a friend about this talk:

This talk is included in these lists:

Note that ex-directory lists are not shown.


© 2006-2023, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity